October 24, 2008Cancer Drug Vidaza(R) Receives Positive Opinion from European - Genetic Engineering News Cancer Drug Vidaza(R) Receives Positive Opinion from European - Genetic Engineering News
-- Acute Myeloid Leukemia (AML) with 20-30 percent blasts and multi-lineage dysplasia, according to World Health Organization (WHO) classification The positive opinion includes important survival data from the AZA-001 trial in higher-risk MDS Source: www.genengnews.com Lilly says EU agency opposes new Cymbalta use - Boston Globe INDIANAPOLIS— A panel of European regulators have recommended against approving antidepressant Cymbalta as a treatment for the pain disorder fibromyalgia, drugmaker Eli Lilly and Co. said Friday. The "negative opinion" comes from the Committee for Source: www.boston.com FDA panel to vote on new version of Genzyme drug - BusinessWeek The Food and Drug Administration will ask a panel of experts next week whether studies by biotech firm Genzyme Corp. support approval of a new version of its drug Myozyme. Cambridge, Mass-based Genzyme already markets Myozyme to patients with Pompe Source: www.businessweek.com Auxilium Pharmaceuticals, Inc. and CPEX Pharmaceuticals, Inc. Receive - MSN MoneyCentral Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) today announced that they have received a notice from Upsher-Smith Laboratories, Inc. advising of the filing by Upsher-Smith Laboratories, Inc. of an Source: news.moneycentral.msn.com Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel - Carolina Newswire DURHAM, N.C. -- Addrenex Pharmaceuticals announced that the U.S. Food and Drug Administration has approved its Investigational New Drug Application (IND) for ADX415, a novel hypertension drug. With the approval, Addrenex has launched a phase 2 Source: carolinanewswire.com # posted by Network @ 6:00 AM
 |
Subscribe to Posts [Atom]